Status: Recruiting
Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older
This phase 1 study in China will evaluate the safety and immunogenicity of the Recombinant Zoster Vaccine, LYB004 in adults aged 40 years and older.
Participants needed: 92
Trial details
Phase: Phase 1Age: 40+Biological sex: AllType: InterventionalSponsor: Guangzhou Patronus Biotech Co., Ltd.Updated: Apr 1, 2025Locations: 1
Eligibility criteria
Residents aged 40 years and older (at the time of screening), regardless of gend... [+3]
Axillary temperature ≥ 37.3°C; [+11]